glecaprevir/pibrentasvir
Brand names: Mavyret
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Drug Pricing (NADAC)
Brand Price
$152.83/unit
Generic Available
No
ABBVIE
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6.
Common side effects
Headache, Feeling tired, Nausea
Key warnings
Mavyret can cause hepatitis B to become active again if you have had it in the past.
How It Works
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
How to Take It
Take Mavyret tablets or oral pellets once a day, at the same time each day. Always take Mavyret with food. For adults and children 12 years and older, the usual dose is three tablets daily. For children 3-12 years old, the dose is based on weight. Your doctor will tell you how long to take Mavyret, usually for 8-16 weeks.
Pregnancy & Breastfeeding
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Missed Dose
If you miss a dose of Mavyret, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time.
Storage
Store Mavyret tablets and oral pellets at or below 86°F (30°C).
Side Effects (from patient reports)
Based on 8,300 FDA adverse event reports.
Serious Warnings
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Known Drug Interactions
Antimycobacterials: Rifampin ↓ glecaprevir ↓ pibrentasvir Coadministration is contraindicated because of potential loss of therapeutic effect [see Contraindications ( 4 ) ] .
Mechanism: Rifampin lowers the levels of the hepatitis C medicine in your body. This makes the treatment less effective and may prevent it from curing the infection.
What to do: Do not take these medications together because the hepatitis C treatment will not work correctly.
Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.
Mechanism: These drugs can cause rosuvastatin levels to rise in your body, which may increase the risk of side effects.
What to do: Your doctor should start you on a low 5 mg dose of rosuvastatin and keep the total daily dose at 10 mg or less.
Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.
Mechanism: These hepatitis C drugs block the pathways your body uses to remove rosuvastatin, leading to higher levels of the statin in your blood. This can increase your risk for serious side effects.
What to do: Your doctor should start your rosuvastatin at 5 mg daily and keep the dose at or below 10 mg per day.
Immunosuppressants: Cyclosporine ↑ glecaprevir ↑ pibrentasvir MAVYRET is not recommended for use in patients requiring stable cyclosporine doses > 100 mg per day.
Mechanism: Cyclosporine causes the levels of glecaprevir and pibrentasvir to increase in your body. This happens because cyclosporine interferes with how the body processes these medications.
What to do: This combination is not recommended if you take more than 100 mg of cyclosporine per day. Your doctor may need to review your current medications before starting this treatment.
glecaprevir/pibrentasvir ↑ glecaprevir ↑ pibrentasvir Co-administration of darunavir/ritonavir with glecaprevir/pibrentasvir is not recommended.
Mechanism: Darunavir increases the amount of glecaprevir and pibrentasvir that stays in your body. This can make the hepatitis C medication more likely to cause side effects.
What to do: This combination is not recommended, so you should ask your doctor for a different treatment option.
Common Questions
How long will I need to take Mavyret?
Can I take Mavyret if I have kidney problems?
Can I take Mavyret if I have HIV?
What should I do if I vomit after taking Mavyret?
Can I drink alcohol while taking Mavyret?
Will Mavyret interact with other medications I am taking?
How will I know if Mavyret is working?
What if I have side effects from Mavyret?
Can children take Mavyret?
Is there a generic version of Mavyret?
What are the common side effects of glecaprevir/pibrentasvir?
Does glecaprevir/pibrentasvir interact with other medications?
What drug class is glecaprevir/pibrentasvir?
Is glecaprevir/pibrentasvir safe during pregnancy?
Related Medications in NS3/4A/NS5A Inhibitor (HCV)
Other drugs grouped near glecaprevir/pibrentasvir — same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with glecaprevir/pibrentasvir →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with glecaprevir/pibrentasvir →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with glecaprevir/pibrentasvir →
anidulafungin
Eraxis
Eraxis is an antifungal medicine.
Compare with glecaprevir/pibrentasvir →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with glecaprevir/pibrentasvir →
Compare glecaprevir/pibrentasvir vs acyclovir side-by-side →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Related Health & Safety Data
🩺 Find a Doctor
Search prescribers for NS3/4A/NS5A Inhibitor (HCV)
🏨 Hospital Quality
CMS hospital ratings, safety scores & patient outcomes
💊 Supplement Data
NIH DSLD — check supplement ingredients & label claims
🍽️ Food Safety Alerts
FDA recalls, inspections & outbreak investigations
⚠️ Product Recalls
FDA, CPSC & NHTSA recall search
💉 Procedure Costs
Medicare procedure pricing for 9,297 procedures
Save on glecaprevir/pibrentasvir
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for glecaprevir/pibrentasvir
The FDA label for glecaprevir/pibrentasvir (sold under brand names such as Mavyret) classifies it as a prescription-only medication in the NS3/4A/NS5A Inhibitor (HCV) class. Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. Official labeling lists 3 commonly reported side effects, including Headache, Feeling tired, Nausea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 8,300 voluntary reports. The database also lists 38 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.
Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: June 10, 2025
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- FDA Orange Book — approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed — NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) — post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm — standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files — federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database — current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages